Beta Bionics (Nasdaq:BBNX) shares rose slightly after hours today on fourth-quarter results that topped the consensus forecast. Shares of BBNX ticked up about 1% to $14.10 apiece in post-market trading today. The Irvine, California-based automated insulin delivery system developer reported losses of $13.5 million. That equals 38¢ per share on sales of $32.1 million for […]
Beta Bionics
Beta Bionics receives FDA warning letter
Beta Bionics (Nasdaq:BBNX) recently disclosed the receipt of a warning letter from the FDA following an inspection. An FDA inspection of the company’s Irvine, California, facility from June 9, 2025, through June 26, 2025, led to the warning letter. In the letter, the FDA outlined deficiencies in the automated insulin delivery system maker’s response letters […]
Analysts downgrade Beta Bionics on new patient starts miss
Analysts downgraded Beta Bionics (Nasdaq:BBNX) to “Neutral” following preliminary fourth-quarter results that fell shy of expectations. Shares of BBNX fell 35% to $20.86 apiece in early-morning trading today. Beta Bionics, which has completed its first full year as a public company following its IPO last year, pre-announced fourth-quarter revenues of $32 million. That came in […]
The top diabetes tech stories of 2025
As the year comes to a close, it’s time to look back at the numerous innovations across the diabetes technology industry in 2025. Once again, continuous glucose monitors (CGMs) and automated insulin delivery systems took most of the headlines, as the leaders in the space keep building on their platforms while challengers continue to enter […]
Beta Bionics makes iLet available with Dexcom G7 15 Day CGM
Beta Bionics (Nasdaq:BBNX) took to social media to announce the integration of its iLet Bionic Pancreas with Dexcom’s (Nasdaq:DXCM) G7 15 Day continuous glucose monitor (CGM). Dexcom received FDA clearance for people over the age of 18 years old in the U.S. in April for the 15-day version of its latest-generation sensor. Last month, the company announced its […]
Beta Bionics stock rises on Q3 beats, raised full-year guidance, advances iLet offerings
Beta Bionics (Nasdaq:BBNX) shares got a boost after hours today on third-quarter results that came in ahead of the consensus forecast. Shares of BBNX rose around 20% to $29 apiece in post-market trading today. The Irvine, California-based automated insulin delivery device maker reported losses of $14 million. That equals 33¢ per share on sales of […]
The 10 largest diabetes technology companies in the world
What has changed in the last year as diabetes technology developers continue to innovate and advance their offerings? We are seeing the industry form an intriguing niche at the intersection of medtech and consumer devices. Various companies around the world are delivering numerous options when it comes to the type of technology they want to […]
Beta Bionics stock gets a boost on Q2 results, raised guidance
Beta Bionics (Nasdaq:BBNX) shares rose after hours today on raised 2025 guidance and second-quarter results that beat the consensus forecast. The company increased its 2025 guidance for revenues between $88 million and $93 million. It previously projected between $82 million and $87 million. Shares of BBNX ticked up nearly 5% to $15.35 apiece in post-market […]
The biggest diabetes tech stories out of ADA 2025
The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]
Analysts expect Beta Bionics patch pump launch by 2027
BTIG analysts said today that Beta Bionics (Nasdaq:BBNX) expects to launch a new insulin patch pump system in the U.S. by the end of 2027. Marie Thibault, Sam Eiber and Alexandra Pang said the company revealed the new Mint system in a live demonstration at the American Diabetes Association’s 85th Scientific Sessions, outlining its plan […]
